Literature DB >> 29796048

The Role of Botulinum Toxin in the Management of Ophthalmoplegia Secondary to Miller Fisher Syndrome.

Siegfried K Wagner1, Nabil Uddin1, Saurabh Jain1.   

Abstract

Miller Fisher syndrome is an acute demyelinating polyneuropathy classically presenting with ataxia, areflexia, and ophthalmoplegia. The authors report the case of a 27-year-old female, who presented with limb weakness and double vision following a prodromal pharyngitis. Ophthalmic examination revealed fluctuant ophthalmoplegia eventually consistent with bilateral sixth cranial nerve palsies, prompting investigation for anti-ganglioside antibodies, which returned positive. Due to disabling diplopia, the patient was treated with botulinum toxin, with a resulting favourable reduction in the size of strabismus. Four months following her presentation, the patient was orthophoric and resumed normal activities.

Entities:  

Keywords:  Anti-ganglioside antibodies; Miller Fisher syndrome; botulinum toxin; ophthalmoplegia

Year:  2017        PMID: 29796048      PMCID: PMC5958969          DOI: 10.1080/01658107.2017.1355925

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  10 in total

1.  Acute ophthalmoparesis (without ataxia) associated with anti-GQ1b IgG antibody: clinical features.

Authors:  N Yuki; M Odaka; K Hirata
Journal:  Ophthalmology       Date:  2001-01       Impact factor: 12.079

2.  Clinical features and prognosis of Miller Fisher syndrome.

Authors:  M Mori; S Kuwabara; T Fukutake; N Yuki; T Hattori
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

3.  Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.

Authors:  Marianna Spatola; Renaud Du Pasquier; Myriam Schluep; Axel Regeniter
Journal:  Neurology       Date:  2016-03-16       Impact factor: 9.910

4.  Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry.

Authors:  M Koga; M Gilbert; J Li; S Koike; M Takahashi; K Furukawa; K Hirata; N Yuki
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

Review 5.  The Fisher variant of Guillain-Barré syndrome (Fisher syndrome).

Authors:  Lee A Snyder; Vivian Rismondo; Neil R Miller
Journal:  J Neuroophthalmol       Date:  2009-12       Impact factor: 3.042

6.  Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination.

Authors:  Y Nishimoto; M Odaka; K Hirata; N Yuki
Journal:  J Neuroimmunol       Date:  2004-03       Impact factor: 3.478

Review 7.  Fisher's syndrome and group A streptococcal infection.

Authors:  N Yuki; K Hirata
Journal:  J Neurol Sci       Date:  1998-09-18       Impact factor: 3.181

8.  Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies.

Authors:  A Chiba; S Kusunoki; H Obata; R Machinami; I Kanazawa
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

9.  Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles.

Authors:  Jing-Xia Liu; Hugh J Willison; Fatima Pedrosa-Domellöf
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-28       Impact factor: 4.799

Review 10.  Guillain-Barré and Miller Fisher syndromes--new diagnostic classification.

Authors:  Benjamin R Wakerley; Antonino Uncini; Nobuhiro Yuki
Journal:  Nat Rev Neurol       Date:  2014-07-29       Impact factor: 42.937

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.